Jefferies Financial Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jefferies Financial Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.32M	Hold	500,000	–	–	0.06%	214
2025 Q4	$6.59M	Buy	500,000 +475,000	+1,900%	+$5.6M	0.03%	427
2025 Q3	$179K	Buy	25,000 +19,811	+382%	+$1.03M	﹤0.01%	1293
2025 Q2	$245K	Sell	5,189 -4,811	-48%	-$196K	﹤0.01%	1082
2025 Q1	$391K	Buy	10,000 +3,750	+60%	+$162K	﹤0.01%	1136
2024 Q4	$338K	Buy	+6,250	New	+$319K	﹤0.01%	1227
2024 Q2	–	Sell	-12,332	Closed	-$619K	–	1705
2024 Q1	$619K	Buy	12,332 +1,757	+17%	+$95.3K	0.01%	982
2023 Q4	$639K	Buy	+10,575	New	+$545K	﹤0.01%	1121
2023 Q3	–	Sell	-93,789	Closed	-$4.78M	–	1833
2023 Q2	$4.78M	Buy	93,789 +24,076	+35%	+$648K	0.04%	380
2023 Q1	$1.49M	Buy	69,713 +2,059	+3%	+$34.6K	0.01%	753
2022 Q4	$710K	Buy	+67,654	New	+$602K	﹤0.01%	954

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Financial Group's MLTX Position: Q1 2026 in Review

Jefferies Financial Group held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 500,000 shares worth $9.32M. The position accounts for 0.06% of the portfolio, ranked #214.

Jefferies Financial Group first reported a position in MLTX in Q4 2022 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Jefferies Financial Group held 500,000 shares of MoonLake Immunotherapeutics worth $9.32M as of Q1 2026.
Jefferies Financial Group left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
MoonLake Immunotherapeutics made up 0.06% of Jefferies Financial Group's portfolio in Q1 2026, its #214 holding.
Jefferies Financial Group first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 11 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.